Navigation Links
Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
Date:3/5/2009

SOUTH SAN FRANCISCO, Calif., March 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that it will hold a conference call to discuss the Company's fourth quarter and year-end financial results and provide a corporate update, including ongoing development activities for picoplatin, the Company's lead product candidate.

Jerry McMahon, Ph.D., chairman and chief executive officer, Ronald A. Martell, president and chief operating officer, Greg Weaver, chief financial officer, and Robert De Jager, M.D., FACP, chief medical officer, will host the call beginning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on Thursday, March 12. A press release for the fourth quarter and year-ended December 31, 2008, will be released before market opening on March 12.

To participate in the live call by telephone, please dial 877-719-9791 from the U.S. or 719-325-4811 for international callers. In addition, the live conference call is being webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com. A replay of the webcast will be available on the Company's website for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated w
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
2. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
3. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
4. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
5. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
6. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
7. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
8. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
9. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
10. Poniard Pharmaceuticals Announces Upcoming Conference Participation
11. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... January 29 Circassia Ltd, a specialty,biopharmaceutical ... today that it has successfully raised GBP11 ... funding. The investment,syndicate includes new investors Goldman ... investors, including Imperial Innovations and Lansdowne,Partners., ...
... Ill. Carbon nanotubes have a sound future ... the worlds first all-nanotube transistor radios to prove ... provide all of the active functionality in the ... implementation of carbon-nanotube materials into high-speed analog electronics ...
... 2008 -- NanoJapan, a unique, Rice University-based program ... Japan with a targeted undergraduate research internship in ... Education,s (IIE) prestigious Andrew Heiskell Award for Innovation ... years ago to promote and honor the most ...
Cached Biology Technology:Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding 2New kind of transistor radios shows capability of nanotube technology 2Rice wins innovation award for international program 2
(Date:4/15/2014)... BETHESDA, Md. (April 15, 2014) The American ... 2014 award winners. All awards will be presented ... San Diego Marriott Hotel on Tuesday, April 29th at ... Biology (EB). , The 2014 award winners ... Jeffrey Laitman, PhD, of the Icahn School of ...
(Date:4/15/2014)... it has become clear that the genetic code ... addition to the well-known building blocks adenine, cytosine, ... important role. Scientists now assume that the newly ... layer of information that extends and complements the ... umlauts that extend the standard alphabet," explained Professor ...
(Date:4/14/2014)... 32-year study of subarctic forest moths in Finnish Lapland ... climate change on animals and plants because much of ... analyzed populations of 80 moth species and found that ... throughout the study period, from 1978 to 2009. During ... rose 3.5 degrees Fahrenheit, and winter precipitation increased as ...
Breaking Biology News(10 mins):American Association of Anatomists 2014 award winners 2German Research Foundation approves new priority program in the life sciences 2Moth study suggests hidden climate change impacts 2Moth study suggests hidden climate change impacts 3
... University of Granada (UGR) have compared the disaster caused by ... 11 years ago with the biggest species extinction known to ... scientists say that carrying out comparisons of this kind will ... mass extinctions. Until now, scientists used to study the ...
... , SUNNYVALE, Calif. and LIVERPOOL, England , ... intelligent video, announced that a major UK airport has completed the ... Vidient,s SmartCatch video analytics suite, while a second UK airport, ... , The SmartCatch system is a major component of the MFlow ...
... 1, 2010) -- Mapping DNase I hypersensitive sites ... regulatory elements such as promoters, enhancers, silencers, insulators, and ... provide access for transcription factors, are selectively digested by ... to then identify these hypersensitive sites. In the ...
Cached Biology News:Aznalcóllar disaster compared with Cretaceous mass extinction 2Vidient SmartCatch Protecting Exit Lanes at Major UK Airport 2Vidient SmartCatch Protecting Exit Lanes at Major UK Airport 3High-throughput analysis of gene regulation, DNA synthesis in Cold Spring Harbor Protocols 2
Quartz-Halogen, 100 W, High Intensity...
... 1;heading 2;Many mammalian ... experimental situations create ... transfection and other ... ViraPower Lentiviral Expression ...
The product contains 10 ml Dynabeads Epoxy (4.5 m). Supplied at 4 x 10 8 beads/ml...
...
Biology Products: